Brokerage firm UBS Maintains its rating on Foundation Medicine Inc(NASDAQ:FMI). In a research note issued to the investors, the brokerage major Raises the price-target to $22.00 per share. The shares have been rated Neutral. The rating by UBS was issued on Sep 21, 2016.
In a different note, On Aug 3, 2016, Janney Capital said it Downgrades its rating on Foundation Medicine Inc. The shares have been rated ‘Sell’ by the firm.
Foundation Medicine Inc (FMI) shares turned negative on Tuesdays trading session with the shares closing down -0.16 points or -0.67% at a volume of 1,79,731. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $23.98. The peak price level was also seen at $23.98 while the days lowest was $23.43. Finally the shares closed at $23.6. The 52-week high of the shares is $25.31 while the 52-week low is $13.34. According to the latest information available, the market cap of the company is $824 M.
Foundation Medicine Inc(FMI) last announced its earnings results on Aug 2, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $28.24M. Analysts had an estimated revenue of $26.66M. Earnings per share were $-0.84. Analysts had estimated an EPS of $-0.80.
Several Insider Transactions has been reported to the SEC. On Sep 6, 2016, David Daly (Chief Commercial Officer) sold 551 shares at $20.48 per share price.Also, On Aug 23, 2016, Jason Ryan (Chief Financial Officer) sold 13,863 shares at $23.92 per share price.On Aug 9, 2016, Steven J. Kafka (President & COO) sold 10,000 shares at $24.16 per share price, according to the Form-4 filing with the securities and exchange commission.
Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.